#BestACR20Tweets RT @TheLancetRheum: Results of the NOVESA phase 2 trial of Ziritaxestat in patients with diffuse cutaneous #SSc presented by @sclerodermaUM at #ACR20 Improvements in mRSS and ACR-CRISS with Ziritaxestat, but not in lung outcomes. https://t.co/GCZj64i86c https://t.co/Pd6qGEGOev